Previous 10 |
Surmodics, Inc. (SRDX) Q1 2019 Earnings Conference Call January 30, 2019 05:00 PM ET Company Participants Tim Arens - VP, Corporate Development & Strategy, Interim VP, Finance and CFO Gary Maharaj - CEO, President & Director Conference Call Participants David Saxon - ...
Surmodics (NASDAQ: SRDX ) fiscal Q1 result s ($M): Revenue: 22.2 (+30.6%); Medical Device: 17.3 (+35.2%). More news on: Surmodics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Surmodics (NASDAQ: SRDX ): Q1 Non-GAAP EPS of $0.12 beats by $0.15 ; GAAP EPS of $0.09 beats by $0.14 . More news on: Surmodics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Updates Fiscal 2019 Guidance Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 first quarter ended December 31, 2018 and updated its financial outlook for fi...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Surmodics, Inc. (NASDAQ:SRDX)'s sale ...
Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announce...
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Stericycle, Inc. (NASDAQ:SRCL)'s sale...